Browse Articles

Filter By:

  • In this Tools of the Trade article, Ana Luísa Correia describes the development and use of a tracker of dormant disseminated tumour cells to investigate the distribution and dynamics of dormant reservoirs within and across distant sites.

    • Ana Luísa Correia
    Tools of the Trade
  • Lv, Liu, Mo and colleagues demonstrate that in pancreatic ductal adenocarcinoma cells, gasdermin E transports the transcription factor YBX1 to the nucleus, where it promotes the expression of mucins, thereby providing tumour cells with a barrier against digestive enzymes.

    • Lucia Brunello
    Research Highlight
  • In this Tools of the Trade article, Alejandro E. Mayorca-Guiliani describes the development and use of in situ decellularization, which allows native extracellular matrix to be preserved to address both tumour deconstruction and reassembly.

    • Alejandro E. Mayorca-Guiliani
    Tools of the Trade
  • Guan, Polesso, Wang, et al. report that androgen receptor blockade, in addition to androgen deprivation therapy, enhances the response of T cells to anti-PD1 immune checkpoint inhibitors.

    • Lucia Brunello
    Research Highlight
  • This Review discusses our current understanding of tumour-infiltrating B lymphocytes (TIL-Bs) in human cancers, considering the role of TIL-Bs across the major facets of cancer immunity. The authors also discuss strategies to harness the cell-based and antibody-based effector mechanisms of TIL-Bs to enable a new generation of cancer immunotherapies.

    • Céline M. Laumont
    • Allyson C. Banville
    • Brad H. Nelson
    Review Article
  • In this Tools of the Trade article, Eunhee Yi describes the development and use of a method called ecTag, which allows imaging and tracking of extrachromosomal DNA in live cancer cells.

    • Eunhee Yi
    Tools of the Trade
  • This Review provides an overview of cancer-related actions of pattern recognition receptors, including both immune and non-immune functions that influence cancer mechanisms as well as the potential to target pattern recognition receptors for cancer drug development and biomarker discovery.

    • Si Ming Man
    • Brendan J. Jenkins
    Review Article
  • North, Benbarche et al. engineered synthetic introns that were spliced specifically in cancer cells expressing the mutant spliceosome factor SF3B1. This led to expression of herpes simplex virus-thymidine kinase and vulnerability of cancer cells to treatment with the antiviral drug ganciclovir.

    • Ulrike Harjes
    Research Highlight
  • In recent years, research in the field of ferroptosis in cancer has risen steeply in part owing to its potential to be targeted. In this Review, Lei et al. provide an up-to-date synthesis of the roles and mechanisms of ferroptosis in tumour growth and progression, including its function in tumour immunity, highlighting it as a vulnerability that can be exploited for cancer therapy.

    • Guang Lei
    • Li Zhuang
    • Boyi Gan
    Review Article
  • Cancer survivors have been increasingly advocating for research into the long-term effects of their treatments. In this World View, Forster explains why cancer survivors must be included in every stage of the research process to ensure innovation in the field.

    • Victoria J. Forster
    World View
  • Nolan et al. used a mouse model of acute radiation exposure to reveal that radiotherapy can create a pro-metastatic lung microenvironment, an effect mediated by neutrophils.

    • Anna Dart
    Research Highlight
  • Dysregulation of cyclin-dependent kinase 4 (CDK4) and CDK6, regulators of the cell cycle, favours the growth and survival of several cancer types. Owing to this, CDK4 and CDK6 inhibitors were developed and are currently approved for the treatment of advanced hormone receptor-positive breast cancer. This Review describes how we are only now beginning to fully understand their mechanisms of action and provides a new framework for conceptualizing their activity, which might enable expansion of the clinical opportunities of these agents.

    • Shom Goel
    • Johann S. Bergholz
    • Jean J. Zhao
    Review Article
  • Kobayashi et al. describe a role for silent mutations in creating functional KRAS-Q61K and develop a strategy that could potentially target this mutant as well as other RAS-Q61X mutations.

    • Sarah Seton-Rogers
    Research Highlight
  • Complex therapies and multimodal interventions have become the gold standard approach for many of the most aggressive tumour types. However, there is a lack of models that enable the development and clinical translation of such treatment concepts. In this Comment, Saur and Schnieke present an argument for porcine cancer models filling this gap.

    • Dieter Saur
    • Angelika Schnieke
    Comment
  • In this Journal Club, Abbas and Kurian discuss a study showing that using iron selenide quantum dots as biometric probes is superior to conventional organic fluorophores — with higher biocompatibility and quantum yield — in detecting tumour cell growth both in vitro and in vivo.

    • Muneer Abbas
    • Philip Kurian
    Journal Club
  • In this Journal Club, H. Mir and S. Singh discuss a study that established the significance of signalling via the G-protein-coupled receptors CXCR1 and CXCR2 in the extrusion of neutrophil extracellular traps, which can be targeted for cancer therapy.

    • Hina Mir
    • Shailesh Singh
    Journal Club
  • mRNA vaccines have proven safe and effective in preventing serious illness and death during the COVID-19 pandemic. In this Comment, Morris and Kopetz argue that these technologies offer a novel approach towards personalizing immune-based treatments for patients with cancer with the potential for immune activation beyond commonly utilized immunotherapies.

    • Van K. Morris
    • Scott Kopetz
    Comment
  • This Review discusses mechanisms by which tumour ecosystems adapt to therapeutic stresses and how these could be exploited, as well as challenges associated with tumour heterogeneity. It provides an integrative framework to identify and target vulnerabilities that arise from adaptive responses to overcome cancer therapy resistance.

    • Marilyne Labrie
    • Joan S. Brugge
    • Ioannis K. Zervantonakis
    Review Article